Goserelin

Generic Name: Goserelin

Brand Names: Zoladex

Drug Type: Small Molecule

Chemical Formula: C_₅₉H_₈₄N_₁₈O_₁₄

CAS Number: 65807-02-5

Unique Ingredient Identifier: 0F65R8P09N

Background: Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return...

Indication: Goserelin is indicated for:

Associated Conditions: Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate

Associated Therapies: Palliative Treatment

Clinical Trials

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Phase 3

Active, not recruiting

Conditions: Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Breast Adenocarcinoma
HER2/Neu Negative
Locally Advanced Breast Carcinoma
Metastatic Breast Carcinoma
Recurrent Breast Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Entinostat
Drug: Exemestane
Drug: Goserelin
Drug: Goserelin Acetate
Procedure: Magnetic Resonance Imaging
Other: Placebo Administration
Other: Quality-of-Life Assessment

First Posted Date: 2014-04-16

Last Posted Date: 2024-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 608

Registration Number: NCT02115282

Locations: 🇺🇸
Eisenhower Medical Center, Rancho Mirage, California, United States
🇺🇸
Mercy Cancer Center - Sacramento, Sacramento, California, United States
🇺🇸
Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States

and more 653 locations

The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer

Phase 2

Conditions: Metastatic Breast Cancer

Interventions: Drug: Fulvestrant
Drug: Anastrozole
Drug: Goserelin

First Posted Date: 2014-02-26

Last Posted Date: 2014-02-26

Lead Sponsor: Hospital Affiliated to Military Medical Science, Beijing

Target Recruit Count: 180

Registration Number: NCT02072512

Locations: 🇨🇳
307 Hospital, Beijing, Beijing, China

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Ibrance
Drug: Bicalutamide
Drug: Zoladex
Drug: Lupron Depot

First Posted Date: 2014-02-11

Last Posted Date: 2020-09-16

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 72

Registration Number: NCT02059213

Locations: 🇺🇸
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States

and more 5 locations

Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Bevacizumab
Drug: Letrozole
Drug: Anastrozole
Drug: Exemestane
Drug: Fulvestrant
Drug: Goserelin
Drug: leuprorelin

First Posted Date: 2013-11-21

Last Posted Date: 2022-08-04

Lead Sponsor: Japan Breast Cancer Research Group

Target Recruit Count: 160

Registration Number: NCT01989780

Locations: 🇯🇵
Japan Breast Cancer Research Group, Chuo-ku, Nihonbashi, Koami-cho, Tokyo, Japan

A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: degarelix
Drug: Goserelin

First Posted Date: 2013-10-17

Last Posted Date: 2024-10-31

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 234

Registration Number: NCT01964170

Bipolar Androgen-based Therapy for Prostate Cancer (BAT)

Phase 2

Completed

Conditions: Recurrent Prostate Cancer

Interventions: Drug: Testosterone cypionate
Drug: Goserelin
Drug: Leuprolide

First Posted Date: 2012-12-17

Last Posted Date: 2016-12-05

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 33

Registration Number: NCT01750398

Locations: 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Degarelix
Drug: Goserelin

First Posted Date: 2012-12-06

Last Posted Date: 2015-06-23

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 285

Registration Number: NCT01744366

Locations: 🇨🇳
Affiliated Southwest Hospital of 3rd Military Medical University of People's Liberation Army, Chongqing, Chongqing, China
🇨🇳
2nd.Affiliated Hospital of Xi'an Jiaotong University College of Medicine, Xi'an, Shanxi, China
🇨🇳
Cancer Institute & Hospital. Chinese Academy of Medical Sciences, Beijing, Beijing, China

and more 26 locations

Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin

Phase 4

Terminated

Conditions: Uterine Leiomyoma

Interventions: Drug: Dienogest
Drug: Goserelin
Drug: Desogestrel

First Posted Date: 2012-11-30

Last Posted Date: 2020-08-13

Lead Sponsor: University of Sao Paulo

Target Recruit Count: 14

Registration Number: NCT01738724

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Neoplasms

Interventions: Drug: PD0332991
Drug: Anastrozole
Drug: Goserelin
Procedure: Surgery (standard of care)
Procedure: Tumor biopsy

First Posted Date: 2012-11-08

Last Posted Date: 2024-12-03

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 84

Registration Number: NCT01723774

Locations: 🇺🇸
Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic - Rochester, Rochester, Minnesota, United States
🇺🇸
University of Alabama, Birmingham, Alabama, United States

and more 1 locations

Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Zoladex

First Posted Date: 2012-10-24

Last Posted Date: 2017-08-25

Lead Sponsor: Fudan University

Target Recruit Count: 216

Registration Number: NCT01712893

Locations: 🇨🇳
FUSCC, Shanghai, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy